Intratumoral PD‐L2 expression in colorectal cancer,[14] glioma,[15] and prostate cancer,[16] and intratumoral FasL expression in gastric cancer,[17] breast cancer,[18] and esophageal squamous‐cell carcinoma[19] are commonly observed. This evidence concerns the gene PDCD1LG2 and prostate carcinoma.